tion in departments of physiology, and has thus developed with that connexion and outlook. The most popular field of investigation is that of the autonomic nervous system and the tissues and glands that it controls. There has been concentration more on perfecting and producing new techniques for investigating this system than on producing new drugs. Academic pharmacology has made an invaluable contribution to the understanding of the functioning of this system and the organs it controls, which techniques have been invaluable to industry in their testing of many new drugs.
Sir Henry Dale was consulted by the University of London in the late 1930s, and asked whether he thought it necessary to have an independent department of pharmacology in each London medical school, and he said 'No'. I doubt if any single word, did more to downgrade the subject than this statement. Nevertheless, cooperation with various departments of chemistry, has unravelled the structure of many complex molecules such as insulin, the octopeptide hormones and vitamins. But, over the rest of the therapeutic drug field, nothing has been done. How worthwhile is it to look at this problem regularly when money is in such short supply?
In Germany the chemical industry has always been strong, and from its interest in dyes, and the observation that antiseptics were usually coloured, we obtained the earliest sulphonamides. Pharmacology in Germany sprang from this rich and powerful chemical industry, as it did in America in the last 100 years with the immigration of many brilliant chemists into the country. Thus in the USA the university departments of pharmacology are often the largest and best equipped in the medical school, rather than the smallest and poorest as is so common over here. Moreover, cooperation between university and pharmaceutical industry in the USA has always been close and on a large scale, whereas in this country it was frowned on for many years and, even now, is nothing like as close and as extensive as it should be for their mutual benefit. Who really cares for the drug requirements of diseases that do not come in for attention by pharmaceutical industry or by university department? The answer is nobody.
As was stressed in the forum, the cost of producing and marketing a new drug these days is prodigiousoften over M£1. Industry must, therefore, tie up this amount of money for ten years or more. Can you blame them then for doing market research to determine in which fields most money is spent on drugs for the patient?
Lack of money is really the root of the problem. Ideally we want a body of people, which includes the pharmaceutical industry, pharmacology departments, the MRC and anyone else who has a useful contribution to make, to survey regularly the therapeutic drug needs in the different and at present neglected areas of medicine. Then enough money must be found to encourage work in these neglected areas. [885] [886] [887] [888] [889] [890] [891] [892] [893] [894] , three main approaches to the development of new drugs become apparent. The first is the empirical approach in which large numbers of new compounds resulting from the industry of the organic chemist are submitted to a battery of routine screening tests in the hope of revealing useful pharmacological properties. These compounds may embody either novel chemical syntheses or only minor modifications in the chemical structures of existing drugs. It is this approach in particular which tends to create a plethora of 'me too' drugs or 'congeners' which differ from existing drugs only in potency and possess no qualitative advantage in terms of selective action, freedom from side-effects or a different pharmacokinetic profile. Dr Herxheimer urged that some restriction should be exercised in the marketing of new drugs of this type which are clearly superfluous. The counter arguments raised in the discussion are not entirely convincing. There is much to be said also, as his remarks suggest, for the better use or further development or even improved formulation of existing drugs. One recalls the salutary paraphrase from Hamlet in the preface of the second edition of Goodman & Gillman (1955, The Pharmacological Basis of Therapeutics. MacMillan, London):
'Those drugs thou hast, and their adoption tried, Grapple them to thy soul with hoops of steel;
But do not dull thy palm with entertainment Of each new-hatch'd, unfledged remedy.'
The increasingly stringent medicolegal requirements for the clinical introduction of new drugs and the fear of new and unpredictable toxic effects also tend towards a more conservative attitude in project selection.
The second and, in theory, the ideal approach is the rational design of new drugs from the study of structure-activity relationships of existing drugs or naturally occurring substances. An outstanding example is the definition of two distinct types of receptor, H 1 and H2, for histamine and the logical development of specific H2 antagonists with their great potential for the treatment of peptic ulceration. As more success is achieved in the isolation and actual chemical identification of drug receptors the rational design of drugs should increase. In the present state of knowledge, as the forum reveals, most companies will seek a sensible compromise between rational design and empiricism.
The third approach is the development of new drugs from chance observations in the laboratory or in the clinic of unexpected-effects of existing drugs. One example is the development of oral hypoglycxmic drugs and of acetazolamide, followed by the thiazide diuretics, from early observations of some of the side-effects of sulphonamides. Dr Cox suggests that for serendipity we should substitute planned but nontargeted research in clinical pharmacology. If I have understood him correctly, the aim would be first to identify drug actions in normal human volunteers and then to design experimental animal models to exploit those actions. This reversal of the normal sequence from animal model to clinical trial is a challenging idea.
Dr Cox focused attention on the type of drug which is used not so much to cure disease but to modify normal function. He cites the example of reproduction and oral contraceptives. An exciting possibility in this context is the production of synthetic antagonists to hormones, including the hypothalamic releasing factors, or of analogues with a more selective or prolonged action. The study of structure-activity relationships in the field of peptide hormones has already produced an antagonist to angiotensin and an analogue, desmopressin, which has practically replaced vasopressin in the treatment of diabetes insipidus. Also interesting was the emphasis on looking to the future in designing new drugs to meet both medical and social needs. The development of drugs to control the learning process and intellectual and emotional functions is highly imaginative, even if slightly reminiscent of Huxley's 'Brave New World'.
One of the most encouraging points to emerge from the presentations by both Dr Main and Dr Cox is the readiness of drug firms to carry out basic research in fields in which they are developing drugs. Some outstanding contributions have been made in this way to our understanding of the basic mechanisms of inflammation, neurohumoral transmission and hypersensitivity and to the pharmacology of prostaglandins, to mention only a few examples. Here I should like to suggest that there is an opportunity for a symbiosis between the drug companies and the universities and it is disappointing that nowhere in the forum is this type of collaboration mentioned. Both speakers referred to the need for experimental models on which to test drugs and for an understanding of the pathology of disease or disease processes to point the direction of new research. It is in these spheres especially that collaboration with departments of pharmacology and medicine in universities should be productive. The British Pharmacological and Pharmaceutical Societies provide a valuable forum at which pharmacologists from industry and university can meet and exchange ideas. There is also the scheme for IRL (Industrial Research Laboratory) candidates to study for a PhD degree with a director of studies from a university department. This is much to be encouraged. However, collaboration could go further than this. Representatives from the drug companies frequently visit departments of pharmacology in medical schools to introduce new drugs. In return those companies might wish to learn what basic research is being conducted in the departments. A further form of collaboration is an interchange between scientists in industry and the university. From advertisements in the medical press it appears that medically qualified pharmacologists are required in industry chiefly to conduct clinical trials or to advise on medical literature, rather than to take part in basic research directed towards the development of new drugs. A freer interchange might lead to a crossfertilization of ideas. Yours Sir, Of the three main approaches to drug discovery and development outlined by Professor Bisset, the third approach appears to be the most promising at the present time, especially because of the disadvantages inherent in the other two. However, most companies adopt a sensible compromise between rational design and empiricism; and an increasing number are recognizing the value of the third approach which is basically concerned with the place of clinical pharmacology. My concern with the empirical approach, apart from not being intellectually very challenging, is that to date it has not provided a satisfactory success rate in terms of new drug discovery. The prospects for the future look even worse. Today no commercial organization can afford to invest for long in ventures as unfavourable as 10 000 to 1 against. Rational design of new drugs awaits a greater understanding of basic pharmacological mechanisms, but will undoubtedly be increasingly important in the future. The topic of 'Drug Discovery' was the subject of the second international meeting of
